EXHIBIT 23.3



                               CONSENT OF KPMG LLP


The Board of Directors
Encysive Pharmaceuticals, Inc.

         We consent to the use of our report on the financial statements of
ICOS-Texas Biotechnology L.P. (a development stage limited partnership)
incorporated by reference herein.

         Our report on the aforementioned financial statements of ICOS-Texas
Biotechnology L.P. dated January 30, 2003, contains an explanatory paragraph
that states that ICOS-Texas Biotechnology L.P. has experienced recurring losses
from operations and has a partners' deficit which raise substantial doubt about
its ability to continue as a going concern. The ICOS-Texas Biotechnology L.P.
financial statements do not include any adjustments that might result from the
outcome of that uncertainty.


/s/ KPMG LLP

Seattle, Washington
August 12, 2003